Recent advances in the diagnosis of drug-induced liver injury.

Diagnosis Drug induced liver injury Liver biopsy RECAM RUCAM

Journal

World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469

Informations de publication

Date de publication:
27 Feb 2024
Historique:
received: 29 09 2023
revised: 03 01 2024
accepted: 03 02 2024
medline: 18 3 2024
pubmed: 18 3 2024
entrez: 18 3 2024
Statut: ppublish

Résumé

Drug-induced liver injury (DILI) is a major problem in the United States, commonly leading to hospital admission. Diagnosing DILI is difficult as it is a diagnosis of exclusion requiring a temporal relationship between drug exposure and liver injury and a thorough work up for other causes. In addition, DILI has a very variable clinical and histologic presentation that can mimic many different etiologies of liver disease. Objective scoring systems can assess the probability that a drug caused the liver injury but liver biopsy findings are not part of the criteria used in these systems. This review will address some of the recent updates to the scoring systems and the role of liver biopsy in the diagnosis of DILI.

Identifiants

pubmed: 38495272
doi: 10.4254/wjh.v16.i2.186
pmc: PMC10941738
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

186-192

Informations de copyright

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All the authors declare that they have no conflict of interest.

Auteurs

Taqwa Ahmed (T)

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.

Jawad Ahmad (J)

Department of Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States. jawad.ahmad@mountsinai.org.

Classifications MeSH